• Catalpol Protocols for Neuroinflammation Research

  2026-08-14

  Catalpol supports mechanism-led studies that connect depressive-like behavior with oxidative stress, NLRP3 inflammasome activation, and microglial neuroinflammation. This workflow translates the CUMS mouse evidence into practical cell, tissue, behavioral, and cross-model assays while preserving clear limits on dose and interpretation.

• Protease Inhibitor Cocktail for OXPHOS Workflows

  2026-08-14

  Protect labile mitochondrial, signaling, and interaction-protein targets during cell and tissue extraction with an EDTA-free, DMSO-based formulation. This practical workflow connects protease control to LRPPRC–dasatinib OXPHOS studies, Western blotting, Co-IP, kinase assays, and tissue profiling.

• AG-490: Designing JAK2/STAT6 Assays

  2026-08-13

  AG-490 and Tyrphostin B42 can help interrogate kinase-dependent immune signaling without reducing complex exosome biology to a single inhibitor result. This guide translates recent hepatocellular carcinoma findings into a rigorous assay strategy for pathway causality, controls, and interpretation.

• GW 4869 in Lupus Nephritis Exosome Research

  2026-08-13

  GW 4869 hydrochloride hydrate provides a mechanistically grounded way to interrogate neutral sphingomyelinase-dependent exosome biology. This article connects the compound to evidence that podocyte-derived, HMGB1-rich exosomes promote glomerular endothelial injury in lupus nephritis while outlining validation strategies, translational limitations, and opportunities beyond a typical product-page description.

• Catalpol, NF-κB, and TrkB in Septic Encephalopathy

  2026-08-12

  This study shows that Catalpol mitigates LPS-induced post-sepsis cognitive impairment in mice by combining anti-inflammatory and neurotrophic effects. Its integrated behavioral, histological, pharmacokinetic, cellular, and target-engagement analyses connect NF-κB suppression with TrkB-mediated BDNF signaling, providing a mechanistic framework for neuroprotection research in septic-associated encephalopathy.

• Norovirus Co-opts NINJ1 for Selective Protein Secretion

  2026-08-12

  Song and colleagues show that murine norovirus repurposes NINJ1, a mediator of plasma membrane rupture, to release the viral protein NS1 while also permitting broad DAMP release. Their combination of CRISPR screening, infection models, protein-interaction analysis, mutagenesis, and mouse experiments defines a caspase-3-dependent secretion mechanism with physiological relevance to enteric infection.

• MYC2–LBD40/42–CRL3BPM4 Tunes Tomato Immunity

  2026-08-11

  The reference study defines a MYC2–LBD40/42–CRL3BPM4 module that balances jasmonate-dependent defense and growth in tomato challenged with Botrytis cinerea. Its central innovation is a dynamic model in which LBD40/42 act as transcriptional brakes, while BPM4-mediated degradation releases defense output when pathogen pressure requires it.

• PCN–GR Control of Hippocampal CYP and Neurotoxicity

  2026-08-11

  The 2025 reference study shows that pregnenolone 16α-carbonitrile produces opposite CYP responses in liver and hippocampus, reducing hippocampal CYP expression and phenytoin-associated neuronal injury. Its genetic and pharmacological evidence points to glucocorticoid receptor signaling, rather than PXR, as the key mediator of this brain-protective response.

• Afatinib in Gastric Cancer Assembloid Research

  2026-08-10

  Afatinib and BIBW 2992 provide a mechanistically precise way to interrogate ErbB dependence in patient-derived gastric cancer assembloids. This article explains how matched tumor–stroma models can distinguish epithelial sensitivity from microenvironment-mediated resistance.

• IPR-803: From PPI Assay to Metastasis Model

  2026-08-09

  IPR-803 is a urokinase receptor inhibitor that connects biochemical uPAR–uPA blockade with invasion, angiogenesis, and metastasis research. This article focuses on how to interpret its assay readouts, model-dependent activity, and translational limitations.

• Patient-Derived Gastric Cancer Assembloids

  2026-08-08

  The reference study develops patient-derived gastric cancer assembloids that combine matched tumor organoids with stromal cell subpopulations from the same tumor. Its findings show that stromal composition alters transcriptional states and drug sensitivity, providing a more physiologically relevant framework for biomarker analysis, resistance studies, and personalized treatment research.

• Ganetespib (STA-9090): Hsp90 Research Guide

  2026-08-07

  Ganetespib, also called STA-9090, is a triazolone-containing small-molecule Hsp90 inhibitor for cancer research. Its reported ATP-pocket binding, client-protein degradation, nanomolar cellular activity, and xenograft regression support its use as a mechanistic research tool rather than a human therapeutic.

• Resazurin Cell Viability Assay Kit: Sensitive Cell Prolifera

  2026-08-07

  Unlock ultra-sensitive, non-toxic quantification of living cells across animal, plant, and microbial systems with the Resazurin Cell Viability Assay Kit. This advanced tool from APExBIO streamlines high-throughput workflows and outperforms legacy assays, making it indispensable for both drug discovery and mechanistic research.

• Decoding ER Stress: Tunicamycin’s Strategic Role in Translat

  2026-08-06

  This thought-leadership article explores Tunicamycin’s mechanistic and translational value as a N-glycosylation inhibitor and endoplasmic reticulum (ER) stress inducer, with actionable guidance for researchers studying inflammation, liver injury, and the unfolded protein response. Drawing on recent findings, including the FASEB Journal’s insights into ATF6-mediated inflammation control, the article bridges rigorous biochemical rationale with translational strategy and protocol optimization, highlighting APExBIO’s Tunicamycin as a gold-standard tool.

• Diterpene Glycosides from Fructus Rubi Suppress DHT-Induced

  2026-08-06

  This study demonstrates that diterpene glycosides from Fructus Rubi ameliorate benign prostatic hyperplasia (BPH) in rat models by targeting androgen receptor and TGF-β/Smad signaling pathways. The findings establish a mechanistic foundation for multitargeted interventions in BPH, with translational relevance for androgen-driven diseases.

7851 records 3/524 page Previous Next 12345 下5页 Last page